Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis?

Journal of Crohn's and Colitis

Volumn 4, Issue 2, 2010, Pages 144-152

  García Sánchez, Valle ^a   Iglesias Flores, Eva ^a   González, Raúl ^a   Gisbert, Javier P ^b   Gallardo Valverde, José María ^a   González Galilea, Ángel ^a   Naranjo Rodríguez, Antonio ^a   de Dios Vega, Juan F ^a   Muntané, Jordi ^a   Gómez Camacho, Federico ^a  

^a HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Calprotectin; Crohn's disease; Fecal marker; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

CALGRANULIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; ENTERITIS; FECES ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROBABILITY; RECEIVER OPERATING CHARACTERISTIC; RELAPSE; REMISSION; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; ULCERATIVE COLITIS;

ADULT; BIOLOGICAL MARKERS; COLITIS, ULCERATIVE; CROHN DISEASE; FECES; FEMALE; HUMANS; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; PHENOTYPE; PROGNOSIS; PROSPECTIVE STUDIES; RECURRENCE; RISK; SENSITIVITY AND SPECIFICITY;

EID: 77952104443     PISSN: 18739946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crohns.2009.09.008     Document Type: Article

References (30)

1. Riley S.A., Mani V., Goodman M.J., Dutt S., and Herd M.E. Microscopic activity in ulcerative colitis: what does it mean?. Gut 32 (1991) 174-178
2. Saverymuttu S.H. Clinical remission in Crohn's disease-assessment using faecal 111In granulocyte excretion. Digestion 33 (1986) 74-79
3. Langhorst J., Elsenbruch S., Koelzer J., Rueffer A., Michalsen A., and Dobos G.J. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol 103 (2008) 162-169
4. Sipponen T., Savilahti E., Kolho K.L., Nuutinen H., Turunen U., and Farkkila M. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis 14 (2008) 40-46
5. Karoui S., Ouerdiane S., Serghini M., et al. Correlation between levels of C-reactive protein and clinical activity in Crohn's disease. Dig Liver Dis 39 (2007) 1006-1010
6. Bitton A., Peppercorn M.A., Antonioli D.A., et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 120 (2001) 13-20
7. Tibble J.A., Sigthorsson G., Bridger S., Fagerhol M.K., and Bjarnason I. Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology 119 (2000) 15-22
8. Yamamoto T., Umegae S., Kitagawa T., and Matsumoto K. Systemic and local cytokine production in quiescent ulcerative colitis and its relationship to future relapse: a prospective pilot study. Inflamm Bowel Dis 11 (2005) 589-596
9. Costa F., Mumolo M.G., Ceccarelli L., et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut 54 (2005) 364-368
10. Brignola C., Campieri M., Bazzocchi G., Farruggia P., Tragnone A., and Lanfranchi G.A. A laboratory index for predicting relapse in asymptomatic patients with Crohn's disease. Gastroenterology 91 (1986) 1490-1494
11. D'Inca R., Di Leo V., Corrao G., et al. Intestinal permeability test as a predictor of clinical course in Crohn's disease. Am J Gastroenterol 94 (1999) 2956-2960
12. Van Kemseke C., Belaiche J., and Louis E. Frequently relapsing Crohn's disease is characterized by persistent elevation in interleukin-6 and soluble interleukin-2 receptor serum levels during remission. Int J Colorectal Dis 15 (2000) 206-210
13. Hanaway P., and Roseth A. Inflammatory biomarkers predict relapse in IBD. Gut 54 (2005) 1346-1347
14. Wright J.P., Young G.O., and Tigler-Wybrandi N. Predictors of acute relapse of Crohn's disease. A laboratory and clinical study. Dig Dis Sci 32 (1987) 164-170
15. Gisbert J.P., Gonzalez-Lama Y., and Mate J. Role of biological markers in inflammatory bowel disease. Gastroenterol Hepatol 30 (2007) 117-129
16. Vermeire S., Van Assche G., and Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys?. Gut 55 (2006) 426-431
17. Vermeire S., Van Assche G., and Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis 10 (2004) 661-665
18. Vermeire S., Van Assche G., and Rutgeerts P. The role of C-reactive protein as an inflammatory marker in gastrointestinal diseases. Nat Clin Pract Gastroenterol Hepatol 2 (2005) 580-586
19. Tibble J.A., Sigthorsson G., Foster R., Forgacs I., and Bjarnason I. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology 123 (2002) 450-460
20. Walkiewicz D., Werlin S.L., Fish D., Scanlon M., Hanaway P., and Kugathasan S. Fecal calprotectin is useful in predicting disease relapse in pediatric inflammatory bowel disease. Inflamm Bowel Dis 14 (2008) 669-673
21. D'Inca R., Dal Pont E., Di Leo V., et al. Can calprotectin predict relapse risk in inflammatory bowel disease?. Am J Gastroenterol 103 (2008) 2007
22. Gisbert J.P., Bermejo F., Perez-Calle J.L., et al. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm Bowel Dis 15 (2009) 1190-1198
23. Lennard-Jones J.E. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 170 (1989) 2-6 discussion 16-19
24. Silverberg M.S., Satsangi J., Ahmad T., et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 19 (2005) 5-36 Suppl A
25. Best W.R., Becktel J.M., Singleton J.W., and Kern Jr. F. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 70 (1976) 439-444
26. de Dombal F. Measuring and quantifying the status of patients with inflammatory bowel disease. In: de Dombal F.T., Myren J., Bouchier I.A.D., and Watkinson G. (Eds). Inflammatory bowel disease. Some international and data reflections (1986), Oxford University Press 267-285
27. Truelove S.C., and Witts L.J. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 2 (1955) 1041-1048
28. Diamanti A., Colistro F., Basso M.S., et al. Clinical role of calprotectin assay in determining histological relapses in children affected by inflammatory bowel diseases. Inflamm Bowel Dis 14 (2008) 1229-1235
29. Modigliani R. Endoscopic management of inflammatory bowel disease. Am J Gastroenterol 89 (1994) S53-65
30. Modigliani R., Mary J.Y., Simon J.F., et al. Clinical, biological, and endoscopic picture of attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 98 (1990) 811-818